Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- Alzheimerâ€™s disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 237265
Licensor grants a non-exclusive, sublicensable license to Licensors Intellectual Property in the Territory solely to use and import nucleic acid sequences encoding for such Additional Antigen in the Field, and to make, have made, use, sell, offer to sell and import Licensee Product(s) containing a nucleic acid sequence encoding for such Additional Antigen in the Field.
For the Licensors Applicator and/or Licensors Custom Components, Licensor grants an exclusive, sublicenseable license under the Licensors Patent Rights and Device Custom Know-How to use, sell, offer to sell and import Licensors Applicators and Licensors Custom Components solely for use with a Licensee Product in the Field.
For the Trademark License, Licensor grants a non-exclusive, sublicensable license in the Field in the Territory to use such trademarks and/or trade names Controlled by Licensor, to the extent that such trademarks and/or trade names relate to Licensors Technology, solely in connection with the use, sale, offer to sell and/or import of Licensee Product.
A single Indication shall include the primary disease and variants or sub-divisions or sub-classifications within such primary disease. For example, for purposes of the Agreement, breast cancer is a single Indication; treatment of and first line treatment of refractory metastatic breast cancer shall be treated as sub-classifications within the single Indication of breast cancer. Treatment and prophylaxis of the same disease (e.g. breast cancer) shall be treated as the same Indication.
IPSCIO Record ID: 230762
This agreement also includes a non-exclusive and exclusive grant back from Licensee to Licensor.
L523S Vaccine shall mean a Vaccine which contains all or a portion of the L523S Antigen.
Licensor Patents shall mean all patents and patent applications; that cover patentable inventions or discoveries made by Licensor solely or together with a Third Party in the course of the Initial Agreement Activities, or, that cover patentable inventions or discoveries that generically or specifically claim all or any part of any L523S, Vaccine, a process for manufacturing any L523S Vaccine, intermediates used in such process or a use of any L523S Vaccine, and which are now or become owned and/or controlled by Licensor and/or under which Licensor otherwise has, now or in the future, the right to grant licenses. Included within the definition of Licensor Patents are any continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, improvement patents and/or foreign counterparts thereof. In no event shall Licensor Patents be deemed to include the Licensee Patents.
Licensee Products shall mean all Licensee Antibody Products and Licensee Vaccine Product.
L523S is an RNA-binding protein as a potential therapeutic target for lung cancer.
IPSCIO Record ID: 243496
Assignment; License-Back. Licensee hereby assigns, transfers, conveys and delivers to Licensor, and Licensor hereby accepts all and every right, title and interest of Licensee in and to the Licensee Patent Rights listed, together with all ancillary rights thereto, including the right to sue for damages by reason of past infringement of any such rights; and the Licensee Intellectual Property owned by Licensee that relates directly to such Licensee Patent Rights (collectively, the Assigned Technology).
Covered Product(s) means any product the Development, Manufacture, use or sale of which is covered by the Licensee Patent Rights or makes use of any Licensee Intellectual Property.
Patent Rights means any and all (a) issued patents and (b) pending patent applications, including all provisional applications, substitutions, divisionals, continuations, continuations-in-part, renewals, and all letters of patent granted with respect to any of the foregoing, (c) patents of addition, restorations, reissues, extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-examinations; (d) inventorâ€™s certificates; and (e) other forms of government issued rights substantially similar to any of foregoing, in each any country in the Territory.
Licensee Intellectual Property means Know-How that is Controlled by Licensee or its Affiliates during the term of this Agreement and that is reasonably necessary or useful for or directly related to the Development, Manufacture or Commercialization of the Covered Products. The term Licensee Intellectual Property does not include (a) any Know-How, which is, as of the Effective Date or later becomes, generally available to the public, excluding Licensee Confidential Information or Know-How Controlled by Licensee or its Affiliates that is publicly disclosed by a Third Party without the consent of Licensee, and Know-How included in Licensee Patent Rights
Licensee Patent Rights means those Patent Rights that Cover Licensee Intellectual Property and are Controlled by Licensee or its Affiliates at any time during the term of this Agreement. Licensee Patent Rights as of the Effective Date are listed which shall be updated in writing from time to time, at least annually, during the term of this Agreement.
Title Flagellin compositions
Application Detials 15/329,870, Filing Date 07-29-2015, Priority Date 07-30-2014
Patent Details N/A
Title Flagellin compositions and uses including effective vaccination
Application Details 15/500,133, Filing Date 07-30-2015, Priority Date 07-30-2014
Patent Details N/A
IPSCIO Record ID: 279292
For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.
Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.
Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.
Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.
The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.
IPSCIO Record ID: 369313
The Field of Use shall mean in vivo, ex vivo, or in vitro prophylactic or therapeutic uses of Licensed Product in the treatment or prevention of cancer in humans.
IPSCIO Record ID: 319599
Licensor hereby grants to Licensee the exclusive option to enter into a license agreement from Licensor for the commercial development, use, and sale of the Technology, products based on the Technology, patents, trade secrets, know-how, and other information related to the Technology;
Materials shall mean the materials and/or intellectual property listed
– Licensor IDF Number 2013-2417 entitled â€œNon-Covalent Loading of Plant Picornavirus Particlesâ€ with US Patent Application US2015/0376578 A1 and EP Patent Application 14754692.3
– Licensor IDF Number 2015-2767 entitled â€œCancer Immunotherapy using Virus Particles with US Patent Application US2018/0133304 A1 and associated foreign patent applications in Japan, China, Canada, Australia, and EP, US non-published patent application with patent serial number 16/612,214, and PCT Patent application with publication number WO 2018/208828 A1
– Licensor IDF Number 2017-3151 entitled â€œMelt Processed Viral Nanoparticle Constructsâ€ with US Patent Application US2019/0350871 A1 and EP Patent Application 17868454.4
Patents shall mean any patent that issues or has issued to Licensor or patent application covering or consisting of the Technology and based on intellectual property in existence as of the Effective Date and any related patent or patent application that is a continuation, continuation-in-part, divisional, or reissue in the United States of America or any other country.
The technology also has direct application as part of a vaccine platform, which has generated promising data in both cancer and infectious diseases, including COVID-19.
The researchers have collectively demonstrated that plant-derived, engineered VLP-based nanotechnologies stimulate a potent anti-tumor immune response in mouse models of metastatic melanoma, ovarian cancer, colon cancer, brain cancer and breast cancer, including companion dogs with metastatic melanoma. This data supports the potential to translate preclinical studies into veterinary applications, such as the treatment of cancer in companion animals, which has high relevance to human melanoma.
This immuno-oncology approach provides a personalized treatment approach by relieving the patientâ€™s tumor-mediated immunosuppression and potentiating anti-tumor immunity against antigens expressed by their own tumor.
The vaccine platform is a natural extension of the immune-stimulating properties of the VLP, combined with directing the response to pre-defined targets. Instead of being a personal vaccine, the modular approach of linking disease specific targets to the VLP allows the potential to rapidly develop countermeasures for pandemics such as COVID-19.
Field of Use shall mean all therapeutic, diagnostic, vaccine and preventive uses of Technology for both veterinary and human applications. Final field of use, including specific indications, which may be narrower than the Field of Use, will be defined in any commercial use license. Said commercial use license will necessarily incorporate developmental, regulatory, and commercial distribution/sales milestones for each product that incorporates any Technology in the Field of Use. For clarification purposes, Technology and Materials shall not be used in or on humans during the Evaluation Period unless Licensee consults with Licensor regarding appropriate, and possibly expanded, indemnification and insurance requirements and receives Licensorâ€™s written authorization to do so. Such authorization will be in Licensorâ€™s sole discretion.
IPSCIO Record ID: 368651
This agreement includes a non-exclusive grant back from Licensee to Licensor.
The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.
Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.
Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.
TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.
The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.
This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).
IPSCIO Record ID: 372620
Licensor grants an exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the Territory other than the United States, for any and all uses in the Territory in the Field.
Licensor grants a non-exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the United States, for any and all uses in the Territory in the Field.
For the Non-Exclusive License Grant, in the event that the making, having made, use, offer for sale, sale or import by Licensee, or its Related Parties, of Licensed Vaccine or Products would infringe during the term of this Agreement a claim of issued letters patent which Licensor owns and which patents are not covered by the grant, Licensor grants, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under such issued letters patent for Licensee and its Related Parties to develop, make, have made, use, sell, offer for sale or import Licensed Vaccines and Products in the Territory.
If Licensee desires to use any trademark identified by Licensor as of the Effective Date for use for the Licensed Vaccine and/or Product in the Territory, it will include without limitation the trademark Heplisavâ„¢.
Hepatitis B Surface Antigen shall mean an immunogenically effective Hepatitis B Surface Antigen protein that is produced by recombinant DNA technology.
x-ISS shall mean the adjuvant, an immunostimulatory sequence (ISS) composed of the 22mer phosphorothioate oligonucleotide sequence 5 TGA CTG TGA ACG TIC GAG ATG A3.
Patents and know-how include
ISSs, Compositions and Methods of Use;
DNA Molecules Coding for FMDH Control Regions; and,
Immunostimulatory Nucleic Acid Molecules.
The trademark is Heplisavâ„¢.
Heplisav-B is a vaccine used in adults 18 and over to prevent hepatitis B, a viral infection of the liver.
IPSCIO Record ID: 372584
Licensor grants a non-exclusive license, including the right to sublicense to Permitted Sublicensees, in the Territory under Licensor Process Patent Claims for use in connection with the manufacture of Covered ODNs.
For the Research license, Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term; provided that Licensee shall not have any rights to use the Licensor Technology for the sale or manufacture for sale of products or processes.
For Licensees Commercialization Rights, Licensee shall have the right to elect, upon notice to Licensor, to market the Product for the Licensees Indication to Specialty Dermatologists as provided.
Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensee.
Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.
Intermediate indications mean all treatment non-Hodgkins lymphoma and prostate cancer (except for Japan), all treatment of Ovarian cancer, third-line treatment of breast cancer or later treatment of breast cancer, second-line or later treatment of NSCLC, second-line or third-line treatment of colorectal cancer.
Minor indication means all treatment of melanoma, T cell lymphoma, renal cell carcinoma, pancreatic cancer, hematological malignancies (other than non-Hodgkins lymphoma), bladder cancer, uterine cancer, cervical cancers and any other cancers in the field.
Licensees Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.
Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.
Licensee owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.
IPSCIO Record ID: 369311
This agreement includes a non-exclusive grant back to Licensor by Licensee.
The Product means BLP25.
BLP25 means Licensors immunotherapeutic vaccine composed of a 25-amino acid sequence of the MUC1 cancer mucin, which vaccine is combined with the adjuvant Lipid A and is encapsulated in a liposomal delivery system, together with any improvements thereto, such as liposomal IL-2 in a kit, synthetic Lipid A, or new delivery formats such as unit dose liquid formulations and unit dose syringes.
MUC1 means cancer associated mucin-1.
L-BLP25 is a synthetic MUC1 peptide vaccine and is a biological response modifier with a chemically synthesized peptide of a cancer-associated protein antigen widely expressed on common cancers. It is designed to induce an immune response to both the synthetic antigen and the natural corresponding antigen as expressed on the cancer.
The field shall mean the use of BLP25 for the prevention and/or treatment of cancers in humans.
IPSCIO Record ID: 332237
6,579,520 – IL-17 related mammalian cytokine polypeptides (IL-17E)
6,569,645 – IL-17 homologous polypeptides and therapeutic uses thereof
Licensee Protein means a IL-17E protein for which either (a) the research and/or at least one Clinical Trial was significantly conducted by Licensee either on its own, or together and in
collaboration with a Sublicensee or (b) Licensee and/or its Sublicensees have exclusive marketing rights worldwide.
IPSCIO Record ID: 279339
Non-Exclusive License Grant. In the event that the making, having made, use, offer for sale, sale, export or import by Licensee, or Licenseeâ€™s Related Parties, of CpG 7909 or Product(s) would infringe, during the term of this Agreement, a claim of issued letters patent which Licensor owns or has the rights to license and which patents are not covered by the grant, Licensor hereby grants to Licensee a non-exclusive, sublicensable, royalty-free license in the Territory under such issued letters patent for Licensee and its Related Parties to make, have made, use, sell, offer for sale, export and/or import CpG 7909 and Product(s) in the Field and in the Territory.
Grant-back License. Licensee will grant to Licensor a non-exclusive, royalty-free, fully-paid up, perpetual worldwide license, including the right to grant sublicenses, to any Licensee Patent arising under the Agreement, which claims recite the use, formulation or any other Improvements solely related to the licensed Licensor Technology (each a â€œLicensorTechnology Improvementâ€) to the extent necessary for Licensor and its sublicensees to practice Licensor Technology Improvements outside the Fields.
CpG 7909 means the Adjuvant Controlled by Licensor that is a proprietary immunomodulatory oligonucleotide containing unmethylated cytosine and guanine dinucleotides whose sequence has been defined by Licensor as CpG 7909 which acts as an agonist of toll-like receptor 9 to modulate the immune response.
Additional Product means any Vaccine which contains CpG 7909 co-formulated with one or more Antigen using the Delivery Method for any and all uses in an Additional Field for which Licensee has exercised its Option under this Agreement.
Licensor Patent Right(s) means all Patent Rights Controlled by Licensor as of the Effective Date, including those listed, or Controlled by Licensor during the Term of this Agreement, which claim or cover CpG 7909 or the use, formulation or Manufacture of CpG 7909 or Products in the Territory.
US 6,194,388 – Immunomodulatory oligonucleotides
US 6,429,199 – Immunostimulatory nucleic acid molecules for activating dendritic cells
US 7,001,790 – Light-emitting aluminum gallium indium nitride compound semiconductor device having an improved luminous intensity
License Patents means any and all issued patents in the Territory which during the Term of this Agreement are Controlled by Licensee or its Controlled Affiliates, which (a) claim or cover Product or (b) which claim or cover a use, formulation or method of manufacture solely related to the licensed Licensor Technology.
a. Prevention of Infection with Hepatitis B Virus
b. Prevention of Infection with Seasonal Interpandemic Influenza Virus
c. Prevention of Infection with Pandemic Influenza Virus
d. Treatment of Alzheimers Disease
Field also includes any Additional Field for which Licensee has exercised the Option under.